Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Jason P Rhodes
AddedMar 31, 2024
UpdatedMay 31, 2026
Jason P Rhodes

Jason P Rhodes

Board Member, Generation Bio

CrunchbaseLinkedIn

Jason P Rhodes's Career

Generation Bio
Generation Bio

Cambridge, MA, US

Board Member· Board
Raze Therapeutics
Raze Therapeutics

Cambridge, MA, US

Board Member· Board
Zyngenia
Zyngenia

Gaithersburg, MD, US

Board Member· Board
Accent Therapeutics
Accent Therapeutics

Lexington, MA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Jason P Rhodes's Career

Generation Bio
Generation Bio
Public$536.4M1502016Cambridge, MA, US
Board Member· Board

Recent news

Vocal Image is using AI to help people communicate betterTechCrunch · 2025

Leadership at Generation Bio

Donald NicholsonDonald NicholsonBoard Member
Catherine Stehman-BreenCatherine Stehman-BreenBoard Member
Andrew ScharenbergAndrew ScharenbergBoard Member
Ron CooperRon CooperBoard Member
Mark D. AngelinoMark D. AngelinoCo-Founder
Charles RowlandCharles RowlandBoard Member
Raze Therapeutics
Raze Therapeutics
Series A$24M92013Cambridge, MA, US
Board Member· Board

Leadership at Raze Therapeutics

David M. SabatiniDavid M. SabatiniCo-Founder
Adam FriedmanAdam FriedmanBoard Member
Joshua RabinowitzJoshua RabinowitzCo-Founder
Hakan GokerHakan GokerBoard Member
Vamsi MoothaVamsi MoothaCo-Founder
Nilesh KumarNilesh KumarBoard Member
Zyngenia
Zyngenia
Public$25M302008Gaithersburg, MD, US
Board Member· Board

Leadership at Zyngenia

David ParkinsonDavid ParkinsonBoard Member
Peter KienerPeter KienerBoard Member
Carlos BarbasCarlos BarbasFounder
Christian ItinChristian ItinBoard Member
Robert GarlandRobert GarlandBoard Member

Similar to Zyngenia

Zebra BiologicsZebra BiologicsConcord, MA, USAntibody Therapeuticsest. 2013Zebra BiologicsConcord, MA, US · est. 2013

US-based Zebra Biologics, Inc. pioneers in discovering and developing advanced antibody therapeutics since 2013.

Seed · $12M8
ZymeronZymeronDurham, NC, USHealthcareest. 2016ZymeronDurham, NC, US · est. 2016

Zymeron: A research-driven biotech firm innovating in healthcare tech for disease detection, prevention, and treatment.

Public · $75k13
Accent Therapeutics
Accent Therapeutics
Series C$178M692017Lexington, MA, US
Board Member· Board

Leadership at Accent Therapeutics

Julie HambletonJulie HambletonBoard Member
Pamela EspositoPamela EspositoBoard Member
Peter TumminoPeter TumminoBoard Member
Robert CopelandRobert CopelandFounder
Shakti NarayanShakti NarayanCEO

Similar to Accent Therapeutics

Accentia BiopharmaceuticalsAccentia BiopharmaceuticalsTampa, FL, USImmunotherapiesest. 2002Accentia BiopharmaceuticalsTampa, FL, US · est. 2002

Accentia Biopharmaceuticals Inc. develops late-stage immunotherapies for respiratory and oncology diseases.

Public · $775k75
Acylin TherapeuticsAcylin TherapeuticsSeattle, WA, USPharmaceuticalsest. 2009Acylin TherapeuticsSeattle, WA, US · est. 2009

Acylin Therapeutics: Seattle-based biopharmaceutical developer specializing in acetylation inhibitors.

Series A · $6.4M9
Adcentrx TherapeuticsAdcentrx TherapeuticsSan Diego, CA, USTherapeuticsest. 2021Adcentrx TherapeuticsSan Diego, CA, US · est. 2021

Adcentrx Therapeutics: Pioneering protein conjugate therapeutics for cancer and life-threatening diseases.

Series A · $101M31
Akttyva TherapeuticsAkttyva TherapeuticsMansfield, MA, USTherapeuticsest. 2006Akttyva TherapeuticsMansfield, MA, US · est. 2006

Akttyva Therapeutics develops targeted treatments for cell barrier dysfunction across various indications.

Angel · $255.5k5

People Similar to Jason P Rhodes

Willix HalimWillix HalimCEO · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoJason RhodesJason RhodesBoard Member · K36 TherapeuticsJeffery GruenJeffery GruenFounder · Raziel HealthGreg CarlisleGreg CarlisleCEO · RazorthinkBrian WongBrian WongBoard Member · Rapt Therapeutics